Phenomena and Processes [G] - Immune system processes [G12] Clinical Trials

82 clinical trials for Phenomena and Processes [G] - Immune system processes [G12] across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema — RECRUITING · PHASE3
• A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity — RECRUITING · PHASE3
• A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants with Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD) — RECRUITING · PHASE1
• A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab with Open-Label Induction, Randomized Double-Blind Maintenance, and Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) with Moderately to Severely Active Crohn's Disease — RECRUITING · PHASE3
• A single-arm, multicenter, phase III study to assess efficacy, pharmacokinetics, safety and tolerability of atrasentan in pediatric patients of 2 to <18 years of age with primary immunoglobulin A nephropathy (IgAN) — NOT_YET_RECRUITING · PHASE3
• Safety and efficacy of steering of immunosuppression based on BKPyV-specific T cells in case of BK Polyomavirus (BKPyV) DNAe- mia after kidney transplantation — NOT_YET_RECRUITING · PHASE4
• Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into platinum/pemetrexed-based first-line treatment for epithelioid malignant pleural mesothelioma — TERMINATED · PHASE2
• A Phase 1 Study of LBL-051 in Patients with Refractory Autoimmune Disease — TERMINATED · PHASE1
• An open non-randomized phase IV trial examining interfering cross-reactivity in serological diagnostics of flavivirus infections in Swedish travelers following vaccination with the live dengue vaccine Qdenga — TERMINATED · PHASE4
• A Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis) — TERMINATED · PHASE3
• AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients with Recurrent or Refractory Active Chronic Graft Versus Host Disease who have Received at least 2 Lines of Systemic Therapy. — TERMINATED · PHASE2
• MAINEPSAN : A Prospective Comparative Randomized Double-blind Placebo-controlled In-Parallel Groups Multicenter, Study to Evaluate the remission MAINtenance using Extended administration of Prednisone in Systemic anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis. — TERMINATED · PHASE3
• Phase II/III double-blind randomized placebo-controlled trial assessing the preventive effect of Clopidogrel on the systemic sclerosis development risk in subjects with specific dysimmunity and Raynaud phenomenon - PSSIT — TERMINATED · PHASE3
• A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus — TERMINATED · PHASE3
• EarLy extra Measles immunisation during a measles Outbreak (ELMO) — NOT_YET_RECRUITING · PHASE4
• An investigator-initiated, single-center academic study in healthy transgender and cisgender persons aged between 18 and 50 years to investigate gender and sex differences in immune responses to meningococcal serogroup B vaccination — TERMINATED · PHASE4
• REpurposed drug evaluation for DEceleration of immunE aging & Mitigation of chronic inflammation (REDEEM) — NOT_YET_RECRUITING · PHASE2
• T cell imaging in kidney transplantation (TIK) — NOT_YET_RECRUITING · PHASE1
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus — TERMINATED · PHASE3
• Multicentre, open-label, randomised, two-arm, parallel-group, superiority study to assess bioavailability and practicability of Envarsus® compared with Advagraf® in de novo liver transplant recipients — TERMINATED · PHASE4
• HEMATOVAC-Immunogenicity of an Anti-pneumococcal Combined Vaccination (PCV13+PPV23 versus PREVENAR20) in Lymphoma — COMPLETED · PHASE4
• A phase IV proof-of-concept study to assess the safety and efficacy of Maribavir to inhibit high Virus Epstein-Barr (VEB) replication among young adult kidney transplant recipie — NOT_YET_RECRUITING · PHASE4
• Safety and immunogenicity of Shingrix vaccination in patients suffering from Psoriasis or Psoriatic arthritis — TERMINATED · PHASE4
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension — OTHER · PHASE3
• TARGET-EBV in MS: A prospective randomized controlled parallel group phase 2b double blinded study to investigate if targeting Epstein Barr Virus with Tenofovir Alafenamide Fumarate compared to placebo as add-on treatment to anti-CD20 therapy reduces neuronal damage in multiple sclerosis — NOT_YET_RECRUITING · PHASE2
• A 60 month, single-arm, proof-of-concept study to induce allogeneic tolerance in deceased donor liver transplant recipients using siplizumab, an anti-CD2 antibody in combination with cyclophosphamide and splenectomy. — COMPLETED · PHASE2
• Prospective, randomized study concerning personalized medicine with Pentaglobin® after interventional infectious source control in peritonitis patients — TERMINATED · PHASE2
• A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren’s Syndrome With Moderate-to Severe Symptom State — TERMINATED · PHASE3
• A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants with Sjögren’s Syndrome (SS) — TERMINATED · PHASE3
• An open, randomized-controlled, multi-center phase-II clinical trial of individualized immunosuppression with intravenously administered donor modified immune cells (MIC) compared to standard-of-care in living donor kidney transplantation — TERMINATED · PHASE2
• A single-arm, open-label, multi-centre, phase I/II study evaluating the safety and clinical activity of QEL-001, an autologous CAR T regulatory cell treatment targeting HLA-A2, in HLA-A2/ A28neg patients that have received an HLA-A2pos liver transplant. — TERMINATED · PHASE2
• Rituximab-induced remission in CIDP (ReCIX study) — TERMINATED · PHASE3
• Crossover study to investigate the safety and tolerability as well as the blood levels after three single doses of Tacrolimus, of which 2 are administered via the cheek mucosa and 1 dose via the mouth (oral). — OTHER · PHASE1
• Long-Term Follow-Up of Patients Who Have Received An Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (CAR-Treg therapy, TX200-TR101) In A Prior Clinical study — TERMINATED · PHASE3
• A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients with Systemic Lupus Erythematosus — TERMINATED · PHASE3
• A randomized, parallel-group, double-blind, placebo-controlled, multicenter trial to investigate the efficacy and safety of subcutaneously administered secukinumab in patients with new-onset of giant cell arteritis (GCA) who are in clinical remission and eligible for treatment with glucocorticoidmonotherapy (GigAINt) — OTHER · PHASE3
• A Danish, double-blind, randomized placebo-controlled clinical trial evaluating allogeneic adipose tissue derived mesenchymal stromal cell therapy in patients with recently diagnosed non-ischemic heart failure with reduced ejection fraction. — OTHER · PHASE2
• ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC) — TERMINATED · PHASE3
• Phase 2 Open Label Prospective Dose-Ranging Clinical Trial with Escalation and Expansion Cohorts to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the Treatment of Hospitalized Patients with Steroid -Refractory Acute Graft-versus-Host Disease — OTHER · PHASE2
• Adjuvant dendritic-cell immunotherapy plus temozolomide following surgery and chemoradiation in patients with newly diagnosed glioblastoma — TERMINATED · PHASE2
• Wilms’ tumor (WT1) antigen-targeted dendritic cell vaccination to prevent relapse in adult patients with acute myeloid leukemia: a multicenter randomized phase II trial — TERMINATED · PHASE2
• CORTIFRENCH - Benefit of a flash dose of corticosteroids in digestive surgical oncology: a randomized, double blind, placebo-controlled trial — TERMINATED · PHASE3
• Ravulizumab dose optimization — TERMINATED · PHASE4
• A controlled, open-label post-authorisation efficacy and safety study in imlifidase desensitised kidney transplant patients with positive crossmatch against a deceased donor prior to imlifidase treatment, including non-comparative registry and concurrent reference cohorts — OTHER · PHASE3
• SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Moderately to Severely Active SLE — TERMINATED · PHASE3
• Combination of baricitinib and anti-TNF vs. baricitinib alone in patients with rheumatoid arthritis: a randomized placebo-controlled phase-III trial - CRI-RA — TERMINATED · PHASE3
• Pan-tumor neoadjuvant basket study of immune check-point inhibition and novel IO combinations (NEOASIS) — TERMINATED · PHASE2
• MCA-derived MSC therapy in renal transplant recipients — TERMINATED · PHASE1
• A randomized controlled open-label multicenter study to assess the efficacy of TCZ in treatment of late/chronic active antibody-mediated rejection in kidney transplant recipients — TERMINATED · PHASE3
• A Phase 2/3, Multicenter, randOmized, Double-blind, placebo-controlled, stUdy to evaLuate the safety and efficacy of Alpha-1 AntiTrypsin for the prEvention of graft versus-host disease in patients receiving hematopoietic cell transplant (MODULAATE Study) — OTHER · PHASE3

Refine this search